Notably, both studies identified that VEGF-C, rather than VEGF-D, was the more crucial pro-lymphangiogenic factor, suggesting that VEGF-C might be a promising therapeutic target in esophageal cancer. The gene discussed is VEGFC; the disease is esophageal cancer.